Sean and Arthur,
It was stated that both Goldman Sachs and Rothchilds Asset Management (through Biotechnology Investments Limited) each have 3,579,754 shares and warrants for an additional 2,020,298 shares apiece. It is stated that each has control and direction over 16.5% of the common outstanding shares of Inflazyme. I assume that is before exercise of the warrants, if it should occur. Also, Royal Trust Corp. of Canada, maybe a GS/Rothchild's friend (just a guess) also purchased 1,949,320 units (each being one share and 1/5 of a warrant to purchase one share) of the recent private placement, and Royal Bank Capital Corp. (Canada?) purchased 1,169,504 units. It looks like a pattern is emerging.
I can't believe that these people would spend their time and money, although the amount spent is a pittance for them, on something they thought wouldn't provide them with outstanding returns, esp. considering that IZP is a microcap. Most analysts for the last several years have been correctly scorning small-cap stocks so why should they risk embarassing themselves on a whim?
My guess as to what might intrigue them the most would be the sheep airway experiments and the lack of toxicity in earlier experiments, on either mice or rats, I think mice, a few years ago. This doesn't prove anything, but there must be a good reason they are reaffirming their belief that this company has a chance, and percentage-wise they've got a huge stake in it.
Just thinking out loud.
HL |
